Pharmacokinetics describes what the body does to a medicine; pharmacodynamics describes what the medicine does in the body. That's pharmacokinetics vs pharmacodynamics, or PK vs PD.
A drug level, a changed blood test and symptom relief are different findings.
Pharmacokinetics vs pharmacodynamics: the official terms
The U.S. Food and Drug Administration (FDA) separates PD and PK on prescription drug labels. Its December 2016 guidance places PD in section 12.2 and PK in section 12.3.
PK follows four processes. Absorption is entering the blood; distribution is spreading through blood and tissues; metabolism means chemical change; excretion is leaving the body.
PD follows wanted and unwanted body responses, including changes in lab measurements.
| Question | Type of evidence |
|---|---|
| How high did the drug level rise? | PK: concentration, meaning the amount in a given volume |
| When did it reach that level? | PK: timing |
| Did a body measurement change after treatment? | PD: biological response |
| Did people feel or function better? | A clinical outcome: a direct health result |
Why researchers keep drug levels and effects separate
A dose tells us how much medicine was given, not the exact blood level. People can absorb, remove and respond to medicines differently.
Exposure-response research connects the amount given, or measured drug levels, with what happens afterward. The FDA's May 2003 exposure-response guidance includes both desired and unwanted responses.
This distinction matters for peptides, short chains of protein building blocks. A laboratory finding about a peptide's effects cannot supply missing measurements of how it moves through a person.
The Selank blood test measured a different peptide
One Selank study makes the distinction concrete. Zozulia and colleagues' 2008 trial, in the Korsakov neurology and psychiatry journal, included 62 patients with generalized anxiety disorder or neurasthenia. Those diagnoses concern persistent anxiety or symptoms such as fatigue and weakness.
Thirty patients received Selank; 32 received medazepam, an anti-anxiety medicine. Researchers used symptom-rating scales and blood tests involving leu-enkephalin, a signaling peptide the body makes.
The reported breakdown measurement concerned leu-enkephalin, not Selank itself. It cannot tell us how long Selank stays in the blood. The comparison also involved Selank alone, so it cannot establish what happens when Semax and Selank are prescribed together.
A brain scan can show a response without showing benefit
A biomarker is a measured feature of the body. A pharmacodynamic biomarker tracks biological activity after a treatment. It might help explain what a medicine does, but it doesn't automatically establish better health.
In Panikratova and colleagues' 2020 study in Doklady Biological Sciences, 52 healthy participants received Semax, Selank or placebo, a comparison treatment without either peptide. They received the treatments separately, not as a pair.
Researchers used functional MRI, a scan that tracks changes in blood oxygen linked to brain activity. Scans took place before treatment and at 5 and 20 minutes afterward.
The study found differences in how signals from certain brain regions varied together. Those scan findings don't establish anxiety relief, better memory or the amount of either peptide reaching the brain.
What remains uncertain for Semax and Selank together
These studies offer different kinds of information: a clinical comparison with a blood marker, and a short imaging experiment. Neither measured the pair's drug levels or responses after giving both together.
A study of the combination would need to identify each ingredient's levels over time and measure relevant responses. It would also need to assess unwanted effects. Separate findings don't establish whether combining the ingredients changes their breakdown, their effects or their risks.
For someone considering a paired prescription, those are unanswered questions. They don't mean the combination has been shown harmful or helpful. The broader Semax and Selank comparison explains their separate research backgrounds.
Mistakes that turn measurements into promises
A changed marker means a clinical benefit. A test can change without showing that someone feels better or functions better. The measurement needs evidence connecting it to the health result being claimed.
A scan at 20 minutes tells us how long a medicine works. It tells us when researchers looked. It doesn't establish when an effect starts, when it ends or how long the drug remains in the body.
More medicine in the blood means more benefit. That relationship needs testing. A higher level can also bring unwanted effects, and a useful response may stop increasing.
Two ingredients have one shared timetable. Each ingredient can move through the body differently. A single duration attached to a paired product needs evidence about that preparation, not an average of two unrelated figures.
How this shows up in a prescription visit
For a Semax/Selank discussion, the useful question is what evidence supports the proposed plan. That includes what was measured, who received the treatment and whether the study tested the same preparation.
A provider also considers the person's symptoms, medical history and current medicines. The prescriber sets the actual dose and follow-up plan. A blood marker from a different peptide or a brief brain scan cannot set that plan by itself.
The follow-up discussion can distinguish a change in a test from a change in daily symptoms. It also gives the person a way to report unwanted effects. Those details matter when evidence about the proposed combination is limited.
Semax / Selank prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that it does not verify compounded drugs' safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
Related terms that help separate the questions
Half-life is the time it takes the level in the blood to fall by half. It describes a drug level, rather than promising a matching duration of benefit.
A surrogate endpoint is a substitute measurement for a health outcome. A marker needs evidence behind that substitution; showing biological activity isn't enough.
PK, PD and clinical outcomes fit together, but each answers a different question. For a prescription discussion, the useful link is between the evidence available and the particular health concern being considered.





